NCT03379233 - A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

January 22, 2019

Study Completion Date

January 22, 2019

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

COMBINATION_PRODUCT

Concept2 inhaler

Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler

COMBINATION_PRODUCT

Concept2 inhaler with patient application

Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring

Trial Locations (9)

12203

Novartis Investigative Site, Berlin

20354

Novartis Investigative Site, Hamburg

23552

Novartis Investigative Site, Lübeck

30625

Novartis Investigative Site, Hanover

04103

Novartis Investigative Site, Leipzig

6419 PC

Novartis Investigative Site, Heerlen

5707 HA

Novartis Investigative Site, Helmond

8934 AD

Novartis Investigative Site, Leeuwarden

7207 AE

Novartis Investigative Site, Zutphen